Technology evaluation: BAY-50-4798, Bayer

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 2, 2004, Pages 221-227

  Hartmann, Gunther ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; CHEMISTRY; EVALUATION; HUMAN; METABOLISM; PATENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; INTERLEUKIN-2; PATENTS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 7944225973     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. 334403 Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE J Am Med Assoc 1994 271 12 907-913
2. 361068 Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial. ANRS 048 study group. Levy Y, Capitant C, Houhou S, Carriere I, Viard JP, Goujard C, Gastaut JA, Oksenhendler E, Boumsell L, Gomard E, Rabian C et al LANCET 1999 353 9168 1923-1929
3. 361091 Structure and expression of a cloned cDNA for human interleukin-2. Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, Hamuro J NATURE 1983 302 5906 305-310
4. 397137 Bayer: Investor Conference in New York. Bayer AG COMPANY PRESENTATION 2000 May
5. 398477 A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, Cheng SL, Delaria KA, Fleischer R, Greve JM, Gundel R et al NAT BIOTECHNOL 2000 18 11 1197-1202
6. 401769 Pharma pipeline - important development projects. Bayer AG COMPANY WORLD WIDE WEB SITE 2001 March 13
7. 409625 American Society of Clinical Oncology - 37th Annual Meeting (Part VIII), San Francisco, CA, USA. Noel H IDDB MEETING REPORT 2001 May 12-15
8. 410112 BAY-50 4798, an interleukin-2 (IL-2) variant, demonstrates selective activation of human and chimpanzee T cells relative to NK cells but shows less selectivity for T-cells from monkeys and rodents. Delaria B, Forte C, Mak P, Greve JM, Rocziak S, Serban D, Tsuchiyama L PROC AM SOC CLIN ONCOL 2001 20 1 Abs 1051
9. 443846 Building Bayer Healthcare: 2001 and Beyond. Bayer AG COMPANY PRESENTATION 2002 March 15
10. 446031 Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells combined with systemic administration of IL-2 selective agonist. Yamada S, Ichikawa N, Kim Y, Tahara H PROC ANNU MEET AM ASSOC CANCER RES 2002 43 Abs 467
11. 452551 Phase I study of interleukin-2 (IL-2) selective agonist BAY-50-4798 (BAY) in patients (pts.) with advanced melanoma (Mel) and renal cell carcinoma (RCC). Margolin KA, Atkins MB, Weber J, Dutcher JP, Ernstoff MS, Smith J, Clark J, O'Day S, Baar J, Sossman J, Lathia C et al PROC AM SOC CLIN ONCOL 2002 21 1 Abs 46
12. 489294 Bayer Biotechnology 2003 product candidate pipeline. Bayer AG COMPANY WORLD WIDE WEB SITE 2003 April 30
13. 494356 R&D: Portfolio. Bayer Yakuhin Ltd COMPANY WORLD WIDE WEB SITE 2003 April 30
14. 503921 Allometric relationships in the pharmacokinetics of BAY 50-4798 in mice, rats, and monkeys. Cheung E, Tseng L, Fleser A, Boes M, Zhao B, Neyer L, Newgren J, Hansen D, Muegge C, Gibbons J, Reynolds T, Lum P ICAAC 2003 43 Abs F-2163
15. 506295 Phase I study of BAY 50-4798, an interleukin-2 (IL-2) selective agonist, in refractory cancer patients. Margolin K, Atkins MB, Weber JS, Dutcher J, Ernstoff MS, Smith J, Lathia C, Smith J, Martell RE CLIN CANCER RES 2001 7 3759S-3760S
16. 506306 Evaluation of the interleukin-2 selective agonist BAY-50-4798 in patients with advance melanoma and renal cell carcinoma, a Cytokine Working Group-coordinated phase I study. Margolin K, Atkins MB, Weber J, Dutcher JP, Ernstoff M, Smith P, Clark J, O'Day S, Flaherty L, Baar J J IMMUNOTHER 2001 24 5 S15
17. 519983 Selective in vitro growth of T lymphocytes from normal human bone marrows. Morgan DA, Ruscetti FW, Gallo R SCIENCE 1976 193 4257 1007-1008.
18. 520068 R & D - Portfolio. Bayer Yakuhin Ltd COMPANY WORLD WIDE WEB SITE 2003 December 31
19. 520202 A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al N ENGL J MED 1987 316 15 889-897
20. 520596 Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC J CLIN ONCOL 1995 13 3 688-696
21. 520597 Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Fisher RI, Rosenberg SA, Fyfe G CANCER J SCI AM 2000 6 1 S55-S57
22. 520598 Subcutaneous recombinant interleukin-2 (rIL-2) in outpatients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial. Tourani JM, Lucas V, Mayeur D, Dufour B, DiPalma M, Boaziz C, Grise P, Varette C, Pavlovitch JM, Pujade Lauraine E, Larregain D et al ANN ONCOL 1996 7 5 525-528
23. 520600 Interleukin 2 and its receptors: Recent advances and new immunological functions. Thèze J, Alzari PM, Bertoglio J IMMUNOL TODAY 1996 17 10 481-486
24. 520601 Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: Association of the p64 IL-2R γ chain with the IL-2R β chain in functional intermediate-affinity IL-2R. Voss SD, Sondel PM, Robb RJ J EXP MED 1992 176 2 531-541
25. 520603 Regulation of IL-2 receptor subunit genes in human monocytes. Differential effects of IL-2 and IFN-γ. Espinoza-Delgado I, Longo DL, Gusella GL, Varesio L J IMMUNOL 1992 149 9 2961-2968
26. 520755 The IL-2 receptor β chain (p70): Role in mediating signals for LAK, NK, and proliferative activities. Siegel JP, Sharon M, Smith PL, Leonard WJ SCIENCE 1987 238 4823 75-78
27. 520757 Receptor-based design of cytokine therapeutics. Shanafelt AB CURR PHARM BIOTECH 2003 4 1 1-20
28. 520758 Therapeutic enhancement of IL-2 through molecular design. Cassell DJ, Choudhri S, Humphrey R, Martell RE, Reynolds T, Shanafelt AB CURR PHARM DES 2002 8 24 2171-2183
29. 520760 Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. Davey RT Jr, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Fyfe G, Lane HC J INFECT DIS 1997 175 4 781-789
30. 523911 Cytokines in cancer pathogenesis and cancer therapy. Dranoff G NAT REV CANCER 2004 4 1 11-21
31. 523920 Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous IL-2 in renal carcinoma. Lissoni P, Barni S, Tancini G, Cazzaniqa M, Frigerio F, Chilelli M, Scardino E, Andres M, Favini P, Meroni T, Verwei F et al ARCH ITAL UROL ANDROL 1997 69 1 41-47
32. 523925 Therapeutic use of interleukin-2 in HIV-infected patients. Pau AK, Tavel JA CURR OPIN PHARMACOL 2002 2 4 433-439
33. 523939 Safety and pharmacokinetics of subcutaneous BAY 50-4798, a recombinant IL-2 selective agonist, in cynomolgus monkeys. Fleser A, Tseng C-ML, Zhao B, Neyer L, Boes M, Reynolds T, Cheung E INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2003 10 Abs 648
34. 523942 The potential role of interleukin-2 in patients with HIV infection. Paredes R, Lopez Benaldo de Quiros JC, Fernandez Cruz E, Clotet B, Lane HC AIDS REV 2002 4 1 36-40
35. 524484 Retroviruses and opportunistic infections - 11th Annual Conference, San Francisco, California, USA. Susman E IDDB MEETING REPORT 2004 February 8-12